EventsThe 3rd International Online Conference on Biomimetics
Published
This submission belongs to the session S2. Biomimetic Materials—Structures, Surfaces and Interfaces of the event The 3rd International Online Conference on Biomimetics
Published date
19 Nov, 2026
Academic Editor
author-avatarYongmei Zheng
Contribution&Funding
Conceptualization,
[Elena Nikolskaya] ; [Maksim Vershinin]
Methodology,
[Maksim Vershinin] ; [Elena Nikolskaya] ; [Ivan Gulyaev] ; [Darya Prilutskaya] ; [Maksim Klimenko] ; [Maria Sokol] ; [Sofia Kleimenova] ; [Mariia Mollaeva]
Software,
[Nikita Yabbarov] ; [Ivan Gulyaev] ; [Maksim Klimenko] ; [Sofia Kleimenova] ; [Mariia Mollaeva] ; [Maksim Vershinin] ; [Darya Prilutskaya]
Validation,
[Maria Sokol] ; [Darya Prilutskaya] ; [Nikita Yabbarov] ; [Maksim Vershinin] ; [Mariia Mollaeva]
Formal analysis,
[Maria Sokol] ; [Maksim Vershinin] ; [Elena Nikolskaya]
Resources,
[Margarita Chirkina]
Writing - original draft,
[Maksim Vershinin]
Writing - review,
[editing] ; [Elena Nikolskaya]
Supervision,
[Elena Nikolskaya]
Project administration,
[Elena Nikolskaya]
Funding acquisition,
[Margarita Chirkina]
Funding: This work was supported by the Russian Science Foundation, research grant No. 25-75-00151 (https://rscf.ru/project/25-75-00151/).
Citation
Maksim Vershinin, Darya Prilutskaya, Maria Sokol, Mariia Mollaeva, Nikita Yabbarov, Margarita Chirkina, Sofia Kleimenova, Maksim Klimenko, Ivan Gulyaev, Elena Nikolskaya, Olga Kamaeva, Development of a Biomimetic PLGA-Based Dactinomycin Delivery System for Melanoma Therapy, in Proceedings of The 3rd International Online Conference on Biomimetics, 24 November–26 November 2026, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Development of a Biomimetic PLGA-Based Dactinomycin Delivery System for Melanoma Therapy

Maksim Vershinin 1
Darya Prilutskaya 1
image
image
Olga Kamaeva 3,4
1. Laboratory of Quantitative Oncology, N.M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia
2. Institute of Biomedical Engineering, NUST MISIS, Moscow, Russia
3. Laboratory of Quantitative Oncology, N.M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia
4. Institute of Biomedical Engineering, National University of Science and Technology «MISIS», Moscow, Russia
Abstract

Introduction.

Dactinomycin is a potent antitumor antibiotic whose clinical use is limited by severe systemic toxicity. Nanoparticle carriers can protect drug cargo, modulate release, improve pharmacokinetics, and potentially promote passive tumor accumulation through the enhanced permeability and retention (EPR) effect. Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable and biocompatible polymer with an established regulatory history and use in FDA-approved drug products. Furthermore, cancer-cell-membrane coatings may retain membrane-associated adhesion proteins and promote homotypic recognition of tumor cells originating from the same cancer type. This study aimed to develop dactinomycin-loaded PLGA nanoparticles functionalized with B16 murine melanoma cell membranes.

Methods.

Dactinomycin-loaded PLGA nanoparticles were prepared by single-emulsion solvent evaporation and optimized using a Box–Behnken design. Particle size, polydispersity index, and zeta potential were determined by dynamic and electrophoretic light scattering; drug content was measured spectrophotometrically, and morphology was evaluated by transmission electron microscopy. B16 membrane material was obtained by hypotonic lysis combined with ultrasonication, centrifugation, and size-exclusion chromatography. Nanoparticles and membrane protein were mixed at a 1:1 mass ratio and processed by probe sonication for 3 min at 45% amplitude and 70 W in an ice bath, followed by centrifugation. Membrane association was evaluated by bicinchoninic acid assay, SDS–PAGE, densitometry, and changes in physicochemical parameters. Drug release was studied in phosphate-buffered saline at +37°C. Cytotoxicity and cellular uptake in B16 cells were assessed by MTT assay and flow cytometry, respectively.

Results.

Optimized uncoated nanoparticles had a mean diameter of 243 nm, a polydispersity index of 0.129, a zeta potential of -22.1 mV, a drug content of 2.06 wt.%, and an encapsulation efficiency of 63.39%. Transmission electron microscopy confirmed a spherical morphology. Approximately 77% of dactinomycin was released within 24 h, and the Weibull model best described the biphasic release profile. Following membrane functionalization, particle diameter increased to 256 nm, the polydispersity index to 0.220, and the zeta potential shifted to -20.8 mV. The biomimetic nanoparticle pellet contained 0.125 mg protein, while SDS–PAGE and densitometry demonstrated membrane-derived protein fractions. Membrane-functionalized nanoparticles showed significantly greater cellular uptake after 4 and 24 h and more than twofold higher cytotoxic activity than uncoated dactinomycin-loaded nanoparticles.

Conclusions.

A biomimetic PLGA-based dactinomycin delivery system coated with B16 melanoma cell membranes was successfully developed and characterized. Membrane functionalization improved nanoparticle interaction with melanoma cells, resulting in enhanced uptake and increased cytotoxicity in vitro. These findings support the potential of this biomimetic platform for targeted melanoma therapy and justify further in vivo investigation.

Keywords
PLGA; nanoparticles; dactinomycin; cancer cell membrane; biomimetic drug delivery; B16; melanoma; homotypic targeting.
Bioinspired Self-Healing and Stretchable Ru(II)-Containing Silicone Materials: From Structure Design to Luminescent Sensing of Toxic Heavy Metals
Electrochromic Hybrids Based on Poly(3,4-ethylenedioxythiophene) and Polydimethylsiloxanes